Sanofi SA

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

09 янв 2024 00:30:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

21 дек 2023 00:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - November 2023

18 дек 2023 14:59:30 Источник Nasdaq GlobeNewswire

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

15 дек 2023 00:30:00 Источник Nasdaq GlobeNewswire

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

15 дек 2023 00:00:00 Источник Nasdaq GlobeNewswire

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

11 дек 2023 15:08:15 Источник Nasdaq GlobeNewswire

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

10 дек 2023 18:31:03 Источник Nasdaq GlobeNewswire

Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

07 дек 2023 00:35:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

06 дек 2023 20:30:00 Источник Nasdaq GlobeNewswire

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

27 ноя 2023 00:30:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - October 2023

23 ноя 2023 11:00:00 Источник Nasdaq GlobeNewswire

Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results

27 окт 2023 00:31:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

27 окт 2023 00:30:00 Источник Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

22 окт 2023 14:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

19 окт 2023 05:00:00 Источник Nasdaq GlobeNewswire

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

18 окт 2023 03:45:00 Источник Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - September 2023

17 окт 2023 13:18:26 Источник Nasdaq GlobeNewswire

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

13 окт 2023 09:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

04 окт 2023 00:00:00 Источник Nasdaq GlobeNewswire

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

04 окт 2023 00:00:00 Источник Nasdaq GlobeNewswire